BMS and Lilly Initiate Phase 2/3 Clinical Trial for Gastric Cancer, Evaluating Opdivo and Cyramza Combination
Seeking a New Breakthrough Beyond Standard Treatment
Progressive gastric and esophageal adenocarcinoma exhibits a rapid deterioration in prognosis upon failure of first-line treatment. Currently, the standard second-line treatment is the combination of Eli Lilly's Cyramza (ramucirumab) and paclitaxel, which has been established as the standard of care. The PARAMUNE (S2303, NCT06203600) clinical trial, led by the U.S. National Cancer Institute (NCI), is evaluating the addition of Bristol Myers Squibb's (BMS) immune checkpoint inhibitor, Opdivo (nivolumab), to this standard regimen. The core objective is to determine whether treatment opportunities can be expanded for patients who have developed resistance to immune-oncology agents in the first-line setting.
Synergistic Effects of Immune and Anti-Angiogenic Mechanisms
This clinical trial assesses the efficacy of a triple combination of the immune checkpoint inhibitor Opdivo, the VEGFR2-targeted antibody Cyramza, and the chemotherapeutic agent paclitaxel. Opdivo activates T cells, while Cyramza blocks the nutrient supply to cancer cells and alleviates immune suppression within the tumor microenvironment. Paclitaxel directly inhibits cancer cell division, inducing apoptosis and enhancing therapeutic synergy. The multifaceted mechanisms of action of these three drugs are expected to complement each other, effectively overcoming treatment resistance that may occur with single-agent use.
Large-Scale Clinical Trial Design Led by the U.S. National Cancer Institute
The PARAMUNE study is a researcher-initiated, multi-center clinical trial led by the SWOG Cancer Research Network, affiliated with the U.S. National Cancer Institute (NCI). Patient recruitment began on June 24, 2024, and the trial employs an efficient clinical design that combines Phase 2 and Phase 3 to rapidly determine efficacy. Cyramza has already received FDA approval in combination with paclitaxel on November 5, 2014, and Opdivo received FDA approval as a first-line treatment for gastric cancer on April 16, 2021. As a government-supported public research initiative, its success is likely to lead to rapid inclusion in global guidelines and adoption as a standard treatment.
Market Expansion and the Interests of Two Multinational Pharmaceutical Companies
The global gastric cancer treatment market is estimated at approximately $4 billion to $8.2 billion in 2025-2026 and is projected to grow to over $11 billion by the mid-2030s. In 2024, Opdivo recorded annual sales of $9.01 billion, and Cyramza recorded $973.3 million, making them both blockbuster products. If this trial is successful, BMS can expand the prescription scope of Opdivo to the second-line treatment setting, and Lilly can defend the strong market position of Cyramza. With unmet needs in the second-line gastric cancer treatment market, the interests of these two major pharmaceutical companies are aligned, and the industry is closely watching the clinical results.
This SWOG S2303 Phase 2/3 trial is a pivotal study that directly compares the efficacy of adding the immune-oncology agent Opdivo (nivolumab) to the global standard of care for second-line gastric cancer, which is the combination of Cyramza (ramucirumab) and paclitaxel. The success of this triple combination therapy, which combines Opdivo (BMS) with annual global sales of $9.01 billion in 2024 and Cyramza (Lilly) with $973.3 million, has the potential to significantly reshape the gastric cancer treatment market, which is estimated at $4 billion to $8.2 billion annually. In particular, given that a large proportion of patients are currently receiving PD-1 inhibitors in the first-line setting, this study is a landmark study that will define the clinical validity of a strategy to maintain or continue immune checkpoint inhibition in the second-line setting. In the short term, the activation of patient recruitment and the announcement of interim results are expected to drive stock momentum for the developing companies. In the medium to long term, it can lead to increased prescription volume and expanded indications due to changes in standard guidelines. If successful, it is expected to restrain the presence of competing pipelines such as MSD's Keytruda and Astellas' Vyloy and establish a dominant position in the second-line gastric cancer market.
Source: ClinicalTrials.gov (api_ct)